Slightly ahead of schedule, MAPS PBC has completed its second Phase 3 study of MDMA-Assisted Therapy (MDMA-AT) for PTSD, with the final participant visit of its MAPP2 trial having taken place. We broke the news via Twitter last week, but today the organisation has shared a press release with further details. MAPS PBC expects to have top-line data in the first quarter of 2023, which will inform a…


Previous articleSurprising Results: Psilocybin Trial for Depression Alleviates Chronic Pain
Next articlePsychedelics Weekly – Oregon Measure 109: Approaching the Proposed Final Rules